Abbott Laboratories recieved a FDA warning letter after failing to investigate and resolve risks related to its implanted heart devices.
In a warning letter, the FDA critiziced Abbott Laboratories for failing to resolve issues related to its cardiovascular devices.
Battery and cybersecurity problems with the heart devices seemed to be a dominant issue.
Concerns about the safety of several implantable defibrillators and its Merlin@home monitor, which allows doctors to care remotely for patients with cardiac devices.
In February, we covered complicatipons with the HeartMate PHP catheter. During procedures to unclog blood vessels, the HeartMate PHP is inserted in the heart to keep blood flowing. The device is used inside the heart with no need for open-chest surgery.
The most recent investigation showed that lithium batteries in the devices weredraining and that the company had “underestimated the occurrence of the hazardous situation.”
As recently as September, the device received praised from the medical community.
Now, the Lab is putting an end to the commercially successful blood pumps use in the United States and Europe after several malfunctions and a patient death.
In late 2016, there were reports that the Merlin@home transmitter used in monitoring certain (then St. Jude Medical) implant devices could be hacked. These hacks could lead to deadly consequences for the patient.
The devices in question are several cardiovascular devices acquired in Abbot’s $25 billion purchase of St. Jude Medical.
In an email to the FDA, the company said that it was looking into the matter.
The FDA has publicly noted that Abbott had failed to provide evidence that the actions had actually been implemented.